Cardinal’s Syncor acquisition
Executive Summary
Cardinal will issue about 13 mil. shares to Syncor stockholders at a ratio of .47 Cardinal shares for each outstanding share of Syncor stock under amended merger agreement. Cardinal put a hold on the acquisition of the nuclear pharmacy company Nov. 6 after discovering Syncor subsidiaries had made improper payments in foreign countries (1"The Pink Sheet" Nov. 11, In Brief). Syncor reached agreements with the Department of Justice and the Securities & Exchange Commission to pay fines and civil penalties totaling $2.5 mil. The merger still has to be approved by Syncor stockholders...
You may also be interested in...
Cardinal’s Syncor acquisition on hold
"There can be no assurance that the transaction involving the acquisition of Syncor by Cardinal Health will be completed," the drug wholesaler said Nov. 6. Cardinal's due diligence investigation discovered "improper payments that had been made in foreign countries by subsidiaries of Syncor," the company said. Cardinal announced its merger agreement with the nuclear pharmacy company in June (1"The Pink Sheet" June 17, p. 9)...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.